Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
- Description:
Water soluble Toll-like receptor 7 (TLR7) agonist. Stimulates cytokine production.
Purity:>98%
Ionomycin calcium salt (HB1001)
Description:Calcium ionophore. Stimulates cytokine production.
Purity:>98%
Ionomycin free acid (HB1002)
Description:Calcium ionophore. Stimulates cytokine production.
Purity:>98%
- Description:
Novel, intracellular covalent chemokine CCR2 negative allosteric modulator (NAM). Binds irreversibly.
Monensin sodium salt (HB4882)
Description:Protein transport inhibitor. Commonly used in cytokine staining.
Purity:>98%
- Description:
PKC activator. Widely used for THP-1 cell differentiation and with ionomycin for stimulating cytokine production
Purity:>99%
Wedelolactone (HB4124)
Description:Selective IKKα and IKKβ kinase activity inhibitor. NF-κB inhibitor.
Purity:>98%
Z-VRPR-FMK (HB4138)
Description:Selective, cell permeable and irreversible MALT1 inhibitor
Purity:>90%